Please provide your email address to receive an email when new articles are posted on . Reteplase was superior to alteplase at reducing disability after acute ischemic stroke. Mortality was similar ...
Please provide your email address to receive an email when new articles are posted on . In a phase 2 study, reteplase demonstrated similar efficacy and safety vs. alteplase for the treatment of acute ...
Alteplase is the standard agent used in early reperfusion therapy, but alternative thrombolytic agents are needed. The efficacy and safety of reteplase as compared with alteplase in patients with ...
BRAVE trial: Reteplase plus abciximab no better than abciximab in improving final infarct size in PC
"Since the final infarct size was similar between the two groups, there was no benefit on the basis of clinical events, and there was a suggestion of more clinical complications in the combination ...
Reteplase more likely to result in excellent functional outcome than alteplase for ischemic stroke within 4.5 hours of symptom onset. HealthDay News — Reteplase is noninferior to alteplase for ...
Percutaneous coronary intervention (PCI) is superior to thrombolysis in patients with acute myocardial infarction (AMI). However, there is an unavoidable delay between the diagnosis of the AMI and the ...
HALLE, Germany--(BUSINESS WIRE)--Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, announced today that it has signed a supply ...
HALLE, Germany--(BUSINESS WIRE)-- Scil Proteins, a private biotech company specialized in the research, development and production of recombinant proteins, announced today that it has signed a supply ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results